CC
SAGE

Casdin Capital’s Sage Therapeutics SAGE Stock Holding History

Casdin Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-90,000
Closed -$4.23M – 42
2023
Q2 		$4.23M Buy
+90,000
New +$4.48M 0.37% 31
2020
Q2 		– Sell
-385,000
Closed -$11.1M – 44
2020
Q1 		$11.1M Buy
385,000
+155,000
+67% +$8.98M 1.17% 25
2019
Q4 		$16.6M Sell
230,000
-170,000
-43% -$20.9M 1.53% 21
2019
Q3 		$56.1M Hold
400,000
– – 5.81% 8
2019
Q2 		$73.2M Hold
400,000
– – 6.85% 5
2019
Q1 		$63.6M Buy
400,000
+88,000
+28% +$12.7M 6.99% 4
2018
Q4 		$29.9M Hold
312,000
– – 5.11% 8
2018
Q3 		$44.1M Buy
312,000
+62,000
+25% +$9.57M 5.36% 5
2018
Q2 		$39.1M Hold
250,000
– – 5.47% 4
2018
Q1 		$40.3M Hold
250,000
– – 7.08% 3
2017
Q4 		$41.2M Buy
250,000
+10,000
+4% +$970K 10.03% 1
2017
Q3 		$15M Sell
240,000
-15,000
-6% -$1.18M 4.22% 12
2017
Q2 		$20.3M Hold
255,000
– – 7.51% 2
2017
Q1 		$18.1M Sell
255,000
-4,500
-2% -$264K 10.69% 1
2016
Q4 		$13.3M Sell
259,500
-7,000
-3% -$330K 10.94% 1
2016
Q3 		$12.3M Buy
266,500
+38,000
+17% +$1.55M 9.94% 2
2016
Q2 		$6.88M Buy
228,500
+39,500
+21% +$1.32M 6.85% 7
2016
Q1 		$6.06M Buy
189,000
+45,989
+32% +$1.62M 6.95% 4
2015
Q4 		$8.34M Buy
+143,011
New +$7.08M 7.37% 2

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Casdin Capital's SAGE Position: Q3 2023 in Review

Casdin Capital sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 90,000 shares — an estimated $4.23M sold.

Casdin Capital first reported a position in SAGE in Q4 2015 and held it in 19 quarters. The position peaked at $73.2M in Q2 2019. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

  • Casdin Capital reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Casdin Capital sold 90,000 Sage Therapeutics shares in Q3 2023, an estimated $4.23M.
  • Casdin Capital first reported a position in Sage Therapeutics in Q4 2015 and held it in 19 quarters.
  • Casdin Capital's Sage Therapeutics position peaked at $73.2M in Q2 2019.
  • 194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Casdin Capital's 13F filing for Q3 2023, filed 14 Nov 2023.